l.National Cancer Institute: SEER Cancer Statistics Review 1975-2001. Available at:

2.Ghia P, Prato G, Scielzo C, et al.: Monoclonal CD5+ and CD5- B-lymphocyte expansions are frequent in the peripheral blood of the elderly. Blood 103:2337, 2004.

3.Cheson BD, Bennett JM, Rai KR, et al.: Guidelines for clinical protocols for chronic lymphocytic leukemia: recommendations of the National Cancer Institute-sponsored working group. Am JHematol 29:152, 1988.

4.Cheson BD, Bennett JM, Grever M, et al.: National Cancer Institute-sponsored working group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 87:4990, 1996.

5. Batata A, Shen B: Diagnostic value of clonality of surface immunoglobulin light and heavy chains in malignant lymphoproliferative disorders. Am J Hematol 43:265, 1993.

6.Taylor HG, Nixon N, Sheeran TP, et al.: Rheumatoid arthritis and chronic lymphatic leukaemia. Clin Exp Rheumatol 7:529, 1989.

7.Weed RI: Exaggerated delayed hypersensitivity to mosquito bites in chronic lymphocytic leukemia. Blood 26:257, 1965.

8.Kolbusz RV, Micetich K, Armin AR, et al.: Exaggerated response to insect bites. An unusual cutaneous manifestation of chronic lymphocytic leukemia. Int J Dermatol 28:186, 1989.

9.Barzilai A, Shpiro D, Goldberg I, et al.: Insect bite-like reaction in patients with hematologic malignant neoplasms. Arch Dermatol 135:1503, 1999.

10. Cerroni L, Zenahlik P, Hofler G, et al.: Specific cutaneous infiltrates of B-cell chronic lymphocytic leukemia: a clinicopathologic and prognostic study of 42 patients. Am J Surg Pathol 20:1000, 1996.

11. Kaddu S, Smolle J, Cerroni L, et al.: Prognostic evaluation of specific cutaneous infiltrates in B-chronic lym-phocytic leukemia. J Cutan Pathol 23:487, 1996.

12. Kuse R, Lueb H: Gastrointestinal involvement in patients with chronic lymphocytic leukemia. Leukemia 11(suppl 2):S50, 1997.

13. Johnston R, Altman KW, Gartenhaus RB: Chronic lym-phocytic leukemia manifesting in the paranasal sinuses. Otolaryngol Head Neck Surg 127:582, 2002.

14. Berkman N, Polliack A, Breuer R, et al.: Pulmonary involvement as the major manifestation of chronic lymphocytic leukemia. Leuk Lymphoma 8:495, 1992.

15. Dear AE, Goldstein D, Hayman JA: Malignant pulmonary lymphoid disease: case reports illustrating anatomical pattern of disease as a prognostic marker. Pathology 28:20, 1996.

16. Ahmed S, Siddiqui AK, Rossoff L, et al.: Pulmonary complications in chronic lymphocytic leukemia. Cancer 98:1912, 2003.

17. Elliott MA, Letendre L, Li CY, et al.: Chronic lympho-cytic leukaemia with symptomatic diffuse central nervous system infiltration responding to therapy with systemic fludarabine. Br JHaematol 104:689, 1999.

18. Pangalis GA, Boussiotis VA, Kittas C: B-chronic lympho-cytic leukemia. Disease progression in 150 untreated stage A and B patients as predicted by bone marrow pattern. Nouv Rev Fr Hematol 30:373, 1988.

19. Haraldsdottir V, Haanen C, Jordans JG: Chronic lympho-cytic leukaemia presenting as renal failure with lympho-cytic infiltration of the kidneys. Neth J Med 41:64, 1992.

20. Phillips JK, Bass PS, Majumdar G, et al.: Renal failure caused by leukaemic infiltration in chronic lymphocytic leukaemia. J Clin Pathol 46:1131, 1993.

21. Comerma-Coma MI, Sans-Boix A, Tuset-Andujar E, et al.: Reversible renal failure due to specific infiltration of the kidney in chronic lymphocytic leukaemia. Nephrol Dial Transplant 13:1550, 1998.

22. Bennett JM, Catovsky D, Daniel MT, et al.: Proposals for the classification of chronic (mature) B and T lymphoid leukaemias. French-American-British (FAB) Cooperative Group. J Clin Pathol 42:567, 1989.

23. Matutes E, Oscier D, Garcia-Marco J, et al.: Trisomy 12 defines a group of CLL with atypical morphology: correlation between cytogenetic, clinical and laboratory features in 544 patients. Br J Haematol 92:382, 1996.

24. Macdonald D, Richardson H, Raby A: Practice guidelines on the reporting of smudge cells in the white blood cell differential count. Arch Pathol Lab Med 127:105, 2003.

25. Rai KR, Sawitsky A, Cronkite EP, et al.: Clinical staging of chronic lymphocytic leukemia. Blood 46:219, 1975.

26. Rai KR: A critical analysis of staging in CLL. In: Gale RP, Rai KR (eds.) Chronic Lymphocytic Leukemia: Recent Progress, Future Direction. New York: Liss; 1987:253.

27. Binet JL, Auquier A, Dighiero G, et al.: A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 48:198, 1981.

28. Hamblin TJ, Davis Z, Gardiner A, et al.: Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 94:1848, 1999.

29. Damle RN, Wasil T, Fais F, et al.: Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 94:1840, 1999.

30. Ibrahim S, Keating M, Do KA, et al.: CD38 expression as an important prognostic factor in B-cell chronic lym-phocytic leukemia. Blood 98:181, 2001.

31. Wiestner A, Rosenwald A, Barry TS, et al.: ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood 101:4944, 2003.

32. Crespo M, Bosch F, Villamor N, et al.: ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 348:1764, 2003.

33. Orchard JA, Ibbotson RE, Davis Z, et al.: ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet 363:105, 2004.

34. Rassenti LZ, Huynh L, Toy TL, et al.: ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lym-phocytic leukemia. N Engl J Med 351:893, 2004.

35. Gunz FW: The epidemiology and genetics of the chronic leukaemias. Clin Haematol 6:3, 1977.

36. Cartwright RA, Bernard SM, Bird CC, et al.: Chronic lymphocytic leukaemia: case control epidemiological study in Yorkshire. Br J Cancer 56:79, 1987.

37. Goldgar DE, Easton DF, Cannon-Albright LA, et al.: Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands. J Natl Cancer Inst 86:1600, 1994.

38. Hallek M, Wanders L, Ostwald M, et al.: Serum beta(2)-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma. Leuk Lymphoma 22:439, 1996.

39. Molica S, Levato D, Cascavilla N, et al.: Clinico-prognostic implications of simultaneous increased serum levels of soluble CD23 and beta2-microglobulin in B-cell chronic lymphocytic leukemia. Eur J Haematol 62:117, 1999.

40. Deegan MJ, Abraham JP, Sawdyk M, et al.: High incidence of monoclonal proteins in the serum and urine of chronic lymphocytic leukemia patients. Blood 64:1207, 1984.

41. Pangalis GA, Moutsopoulos HM, Papadopoulos NM, et al.: Monoclonal and oligoclonal immunoglobulins in the serum of patients with B-chronic lymphocytic leukemia. Acta Haematol 80:23, 1988.

42. Hamblin TJ, Oscier DG, Young BJ: Autoimmunity in chronic lymphocytic leukaemia. J Clin Pathol 39:713, 1986.

43. Morra E, Nosari A, Montillo M: Infectious complications in chronic lymphocytic leukaemia. Hematol Cell Ther 41:145, 1999.

44. Tsiodras S, Samonis G, Keating MJ, et al.: Infection and immunity in chronic lymphocytic leukemia. Mayo Clin Proc 75:1039, 2000.

45. Wijermans PW, Gerrits WB, Haak HL: Severe immunodeficiency in patients treated with fludarabine monophosphate. Eur J Haematol 50:292, 1993.

46. Anaissie EJ, Kontoyiannis DP, O'Brien S, et al.: Infections in patients with chronic lymphocytic leukemia treated with fludarabine. Ann Intern Med 129:559, 1998.

47. Keating MJ, O'Brien S, Lerner S, et al.: Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood 92:1165, 1998.

48. Ultmann JE, Fish W, Osserman E, et al.: The clinical implications of hypogammaglobulinemia in patients with chronic lymphocytic leukemia and lymphocytic lymphosarcoma. Ann Intern Med 51:501, 1959.

49. Shaw R, Szwed C, Boggs D, et al.: Infection and immunity in chronic lymphocytic leukemia. Arch Intern Med 106:467, 1960.

50. Davey FR, Kurec AS, Tomar RH, et al.: Serum immunoglobulins and lymphocyte subsets in chronic lymphocytic leukemia. Am J Clin Pathol 87:60, 1987.

51. Orfao A, Gonzalez M, San Miguel JF, et al.: Surface phe-notype and immunoglobulin levels in B-cell chronic lymphocytic leukaemia. Haematologia 23:49, 1990.

52. Itala M, Helenius H, Nikoskelainen J, et al.: Infections and serum IgG levels in patients with chronic lympho-cytic leukemia. Eur J Haematol 48:266, 1992.

53. Griffiths H, Lea J, Bunch C, et al.: Predictors of infection in chronic lymphocytic leukaemia (CLL). Clin Exp Immunol 89:374, 1992.

54. Molica S, Levato D, Levato L: Infections in chronic lym-phocytic leukemia. Analysis of incidence as a function of length of follow-up. Haematologica 78:374, 1993.

55. Aittoniemi J, Miettinen A, Laine S, et al.: Opsonising immunoglobulins and mannan-binding lectin in chronic lymphocytic leukemia. Leuk Lymphoma 34:381, 1999.

56. Rozman C, Montserrat E, Vinolas N: Serum immunoglobulins in B-chronic lymphocytic leukemia. Natural history and prognostic significance. Cancer 61:279, 1988.

57. Copson ER, Ellis BA, Westwood NB, et al.: IgG subclass levels in patients with B cell chronic lymphocytic leukaemia. Leuk Lymphoma 14:471, 1994.

58. Ebbe S, Wittels B, Dameshek W: Autoimmune thrombo-cytopenic purpura (ITP type) with chronic lymphocytic leukemia. Blood 19:23, 1962.

59. Bergsagel DE: The chronic leukemias: a review of disease manifestations and the aims of therapy. Can Med Assoc J 96:1615, 1967.

60. Lugassy G, Lishner M, Polliack A: Systemic lupus erythe-matosus and chronic lymphocytic leukemia: rare coexistence in three patients, with comments on pathogene-sis. Leuk Lymphoma 8:243, 1992.

61. Ramos-Casals M, Garcia-Carrasco M, Brito MP, et al.: Autoimmunity and geriatrics: clinical significance of autoimmune manifestations in the elderly. Lupus 12:341, 2003.

62. Engelfriet CP, Overbeeke MA, von dem Borne AE: Autoimmune hemolytic anemia. Semin Hematol 29:3, 1992.

63. Hamblin TJ, Oscier DG, Young BJ: Autoimmunity in chronic lymphocytic leukaemia. J Clin Pathol 39:713, 1986.

64. Tertian G, Cartron J, Bayle C, et al.: Fatal intravascular autoimmune hemolytic anemia after fludarabine treatment for chronic lymphocytic leukemia. Hematol Cell Ther 38:359, 1996.

65. Gonzalez H, Leblond V, Azar N, et al.: Severe autoimmune hemolytic anemia in eight patients treated with fludarabine. Hematol Cell Ther 40:113, 1998.

66. Duhrsen U, Augener W, Zwingers T, et al.: Spectrum and frequency of autoimmune derangements in lymphoprolif-erative disorders: analysis of 637 cases and comparison with myeloproliferative diseases. Br J Haematol 67:235, 1987.

67. Diehl LF, Ketchum LH: Autoimmune disease and chronic lymphocytic leukemia: autoimmune hemolytic anemia, pure red cell aplasia, and autoimmune throm-bocytopenia. Semin Oncol 25:80, 1998.

This page intentionally left blank

Was this article helpful?

0 0
Arthritis Relief and Prevention

Arthritis Relief and Prevention

This report may be oh so welcome especially if theres no doctor in the house Take Charge of Your Arthritis Now in less than 5-Minutes the time it takes to make an appointment with your healthcare provider Could you use some help understanding arthritis Maybe a little gentle, bedside manner in your battle for joint pain relief would be great Well, even if you are not sure if arthritis is the issue with you or your friend or loved one.

Get My Free Ebook

Post a comment